Skip to main content

Table 5 Clinical trials using mesenchymal stem cell-based therapies for degenerative disc disease

From: Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

Year, author Stem cells Cell number Number of patients Injection Follow-up (months) Findings
2010, Yoshikawa et al. [13] Autologous BM-MSCs 105 cells/ml 2 Intradiscal, single 24 Improvement in pain score and rehydration of the disc in both patients
2011, Orozco et al. [12] Autologous BM-MSCs 23 ± 5 × 106 10 Intradiscal, single 12 Improvement in pain, disability, and disc hydration
2015, Pettine et al. [33] Autologous BM concentrated cells 121 (±11) × 106 26 Intradiscal, single or double 12 Improvement in pain scores in patients with higher CFU-F concentrations; improvement on MRI (n = 8)
2017, Mesoblast Ltd (unpublished) Allogeneic MPCs in HA carrier 6 × 106 1.8 × 107 100 Intradiscal, single 36 Improvement in VAS and ODI in 6 million MPCs injected group
Present study AT-MSCs in HA carrier 2 × 107 (n = 5) 4 × 107 (n = 5) 10 Intradiscal, single 12 Improvement in VAS, ODI, SF-36 (n = 6); improvement of water content on diffusion MRI (n = 3)
  1. BM-MSC bone marrow derived mesenchymal stem cell, MPC mesenchymal precursor cell, AT-MSC adipose tissue derived mesenchymal stem cell, HA hyaluronic acid, VAS visual analogue scale, ODI Oswestry Disability Index, CFU-F colony-forming unit-fibroblast, SF Short Form, MRI magnetic resonance imaging